HUP0102367A2 - Citokinek által közvetített betegségek kezelésére alkalmas benzamidszármazékok - Google Patents

Citokinek által közvetített betegségek kezelésére alkalmas benzamidszármazékok

Info

Publication number
HUP0102367A2
HUP0102367A2 HU0102367A HUP0102367A HUP0102367A2 HU P0102367 A2 HUP0102367 A2 HU P0102367A2 HU 0102367 A HU0102367 A HU 0102367A HU P0102367 A HUP0102367 A HU P0102367A HU P0102367 A2 HUP0102367 A2 HU P0102367A2
Authority
HU
Hungary
Prior art keywords
alkyl
amino
alkoxy
aryl
group
Prior art date
Application number
HU0102367A
Other languages
English (en)
Inventor
Dearg Sutherland Brown
George Robert Brown
Original Assignee
Astrazeneca Ab,
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9810356.7A external-priority patent/GB9810356D0/en
Priority claimed from GBGB9905970.1A external-priority patent/GB9905970D0/en
Application filed by Astrazeneca Ab, filed Critical Astrazeneca Ab,
Publication of HUP0102367A2 publication Critical patent/HUP0102367A2/hu
Publication of HUP0102367A3 publication Critical patent/HUP0102367A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/84—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/40—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

A találmány citokinek által közvetített betegségek, így gyulladásos ésallergiás megbetegedések ellen alkalmazható (I) általános képletűvegyületekre, gyógyászatilag alkalmazható sóikra és in vivokörülmények között hidrolizálható észtereikre vonatkozik - a képletbenR1 és R2 halogénatomot vagy hidroxil-, alkoxi-, merkapto-, alkil-tio-,alkil-amino-, dialkil-amino-, karboxil-, alkoxi-karbonil-, karbamoil-,alkil-karbamoil-, dialkil-karbamoil-, alkil-szulfinil-, alkil-szulfonil-, aril-szulfinil-, aril-szulfonil-, alkil-amino-szulfonil-,dialkil-amino-szulfonil-, nitro-, ciano-, ciano-alkil-, hidroxi-alkil-, amino-alkil-, alkanoil-amino-, alkoxi-karbonil-amino-,alkanoil-oxi-, alkil-, alkenil-, alkinil-, trifluor-metil-, aril-,aril-alkil-, aril-alkoxi-, heteroaril-, heteroaril-alkil-,heterociklusos- vagy heterociklusos-alkil-csoportot jelent, p és mértéke 0-3, q értéke 0-4, R3 halogénatomot, cianocsoportot vagyalkoxicsoportot jelent, és R4 adott esetben szubsztituált aril- vagycikloalkilcsoportot jelent. Ó
HU0102367A 1998-05-15 1999-05-11 Benzamide derivatives for the treatment of diseases mediated by cytokines HUP0102367A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9810356.7A GB9810356D0 (en) 1998-05-15 1998-05-15 Amide derivatives
GBGB9905970.1A GB9905970D0 (en) 1999-03-17 1999-03-17 Amide derivatives
PCT/GB1999/001491 WO1999059960A1 (en) 1998-05-15 1999-05-11 Benzamide derivatives for the treatment of diseases mediated by cytokines

Publications (2)

Publication Number Publication Date
HUP0102367A2 true HUP0102367A2 (hu) 2001-10-28
HUP0102367A3 HUP0102367A3 (en) 2002-11-28

Family

ID=26313677

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102367A HUP0102367A3 (en) 1998-05-15 1999-05-11 Benzamide derivatives for the treatment of diseases mediated by cytokines

Country Status (23)

Country Link
US (1) US6465455B1 (hu)
EP (1) EP1077930B1 (hu)
JP (1) JP2003505337A (hu)
KR (1) KR100628284B1 (hu)
CN (1) CN1188389C (hu)
AT (1) ATE282023T1 (hu)
AU (1) AU748397B2 (hu)
BR (1) BR9910467A (hu)
CA (1) CA2328699A1 (hu)
DE (1) DE69921804T2 (hu)
ES (1) ES2230853T3 (hu)
HK (1) HK1033753A1 (hu)
HU (1) HUP0102367A3 (hu)
ID (1) ID27285A (hu)
IL (1) IL139710A (hu)
NO (1) NO20005766L (hu)
NZ (1) NZ507143A (hu)
PL (1) PL197181B1 (hu)
PT (1) PT1077930E (hu)
RU (1) RU2205823C2 (hu)
SK (1) SK286247B6 (hu)
TR (1) TR200003355T2 (hu)
WO (1) WO1999059960A1 (hu)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
US7772432B2 (en) 1991-09-19 2010-08-10 Astrazeneca Ab Amidobenzamide derivatives which are useful as cytokine inhibitors
AU739066B2 (en) 1997-09-23 2001-10-04 Astrazeneca Ab Amide derivatives for the treatment of diseases mediated by cytokines
BR9910474A (pt) 1998-05-15 2001-01-02 Astrazeneca Ab Composto derivado de amida, processo para preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
CA2328699A1 (en) 1998-05-15 1999-11-25 Dearg Sutherland Brown Benzamide derivatives for the treatment of diseases mediated by cytokines
IL141183A0 (en) 1998-08-04 2002-02-10 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
ATE266399T1 (de) 1998-08-20 2004-05-15 Smithkline Beecham Corp Neue substituierte triazolverbindungen
ES2211172T3 (es) 1998-09-25 2004-07-01 Astrazeneca Ab Derivados de benzamida y su utilizacion como inhibidores de citoquinas.
BR0009041A (pt) * 1999-03-17 2001-12-26 Astrazeneca Ab Derivado de amida, processo para a preparação deum derivado de amida, composição farmacêutica,uso de um derivado de amida, e, método paratratar doenças ou quadros clìnicos mediados porcitocinas
SK287238B6 (sk) * 1999-03-17 2010-04-07 Astrazeneca Ab Amidové deriváty, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
GB9906566D0 (en) 1999-03-23 1999-05-19 Zeneca Ltd Chemical compounds
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives
EP1235814B1 (en) 1999-11-23 2004-11-03 Smithkline Beecham Corporation 3,4-DIHYDRO-(1H)QUINAZOLIN-2-ONE COMPOUNDS AS CSBP/p38 KINASE INHIBITORS
US6943161B2 (en) 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
EP1844766B1 (en) * 2000-12-18 2012-04-18 Institute of Medicinal Molecular Design, Inc. Inhibitors against the production and release of inflammatory cytokines
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
US20060089395A1 (en) * 2002-06-10 2006-04-27 Susumu Muto Nf-kb activation inhibitors
WO2004004703A1 (ja) * 2002-07-04 2004-01-15 Mitsui Chemicals, Inc. メタフェニレンジアミン誘導体
CA2492033A1 (en) 2002-07-09 2004-01-15 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
EP1663223B1 (en) 2003-09-17 2014-01-01 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Thalidomide analogs as tnf-alpha modulators
GB0324790D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Amide derivatives
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
AU2006306991A1 (en) 2005-10-28 2007-05-03 Takeda Pharmaceutical Company Limited Heterocyclic amide compound and use thereof
CA2629814C (en) * 2005-11-14 2013-12-31 Genentech, Inc. Bisamide inhibitors of hedgehog signaling
EP2004614B1 (en) 2006-04-13 2016-10-19 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Tetrahalogenated compounds useful as inhibitors of angiogenesis
US7671058B2 (en) * 2006-06-21 2010-03-02 Institute Of Medicinal Molecular Design, Inc. N-(3,4-disubstituted phenyl) salicylamide derivatives
WO2008089034A2 (en) * 2007-01-11 2008-07-24 Kemia, Inc. Cytokine inhibitors
EP1992344A1 (en) 2007-05-18 2008-11-19 Institut Curie P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
CN104326937B (zh) * 2014-09-03 2016-08-24 天津市肿瘤研究所 抗肿瘤化合物及其医药用途
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1903899A (en) 1933-04-18 Cabboxylic acid abylides oe the benzene sebies and process oe making
US1909960A (en) 1929-08-06 1933-05-23 Du Pont Intermediate for azo dyes
DE2812252A1 (de) 1978-03-21 1979-10-04 Bayer Ag 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel
US4524168A (en) 1981-11-18 1985-06-18 Ciba-Geigy Corporation Process for the mass coloration of polymers
US4749729A (en) 1984-06-21 1988-06-07 American Cyanamid Company Epoxy resin compositions curable above 160 F. and below 250 F.
AU2552492A (en) 1991-08-23 1993-03-16 United States of America as represented by The Secretary Department of Health and Human Services, The Raf protein kinase therapeutics
GB9816837D0 (en) 1998-08-04 1998-09-30 Zeneca Ltd Amide derivatives
EP0871444A4 (en) 1995-08-10 1999-01-13 Merck & Co Inc 2.5 SUBSTITUTED ARYL PYRROL, THE COMPOSITIONS THAT CONTAIN AND THE USE THEREOF
DE69634822T2 (de) * 1995-08-22 2006-04-27 Japan Tobacco Inc. Amid-verbindungen und ihre anwendung
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
WO1998006715A1 (en) * 1996-08-09 1998-02-19 Smithkline Beecham Corporation Novel piperazine containing compounds
GB9623833D0 (en) 1996-11-16 1997-01-08 Zeneca Ltd Chemical compound
AU739066B2 (en) 1997-09-23 2001-10-04 Astrazeneca Ab Amide derivatives for the treatment of diseases mediated by cytokines
GB9809347D0 (en) 1998-05-05 1998-07-01 Reckitt & Colmann Prod Ltd Compositions
BR9910474A (pt) 1998-05-15 2001-01-02 Astrazeneca Ab Composto derivado de amida, processo para preparação do mesmo, composição farmacêutica, e, uso de um composto derivado de amida
CA2328699A1 (en) 1998-05-15 1999-11-25 Dearg Sutherland Brown Benzamide derivatives for the treatment of diseases mediated by cytokines
IL141183A0 (en) 1998-08-04 2002-02-10 Astrazeneca Ab Amide derivatives useful as inhibitors of the production of cytokines
ES2211172T3 (es) 1998-09-25 2004-07-01 Astrazeneca Ab Derivados de benzamida y su utilizacion como inhibidores de citoquinas.
US6593333B1 (en) 1998-10-01 2003-07-15 Astrazeneca Ab Substituted anilino-quinazoline (or quinoline) compounds and use thereof
SK287238B6 (sk) 1999-03-17 2010-04-07 Astrazeneca Ab Amidové deriváty, spôsob ich prípravy, farmaceutická kompozícia, ktorá ich obsahuje, a ich použitie
BR0009041A (pt) 1999-03-17 2001-12-26 Astrazeneca Ab Derivado de amida, processo para a preparação deum derivado de amida, composição farmacêutica,uso de um derivado de amida, e, método paratratar doenças ou quadros clìnicos mediados porcitocinas
GB9924092D0 (en) 1999-10-13 1999-12-15 Zeneca Ltd Pyrimidine derivatives

Also Published As

Publication number Publication date
EP1077930B1 (en) 2004-11-10
PT1077930E (pt) 2005-03-31
ID27285A (id) 2001-03-22
SK286247B6 (sk) 2008-06-06
BR9910467A (pt) 2001-01-09
KR20010043547A (ko) 2001-05-25
TR200003355T2 (tr) 2001-03-21
US6465455B1 (en) 2002-10-15
DE69921804T2 (de) 2005-10-27
IL139710A (en) 2005-07-25
ES2230853T3 (es) 2005-05-01
CN1188389C (zh) 2005-02-09
PL344185A1 (en) 2001-10-08
HK1033753A1 (en) 2001-09-21
DE69921804D1 (de) 2004-12-16
CN1359371A (zh) 2002-07-17
AU3839299A (en) 1999-12-06
KR100628284B1 (ko) 2006-09-27
NZ507143A (en) 2003-08-29
EP1077930A1 (en) 2001-02-28
JP2003505337A (ja) 2003-02-12
IL139710A0 (en) 2002-02-10
ATE282023T1 (de) 2004-11-15
RU2205823C2 (ru) 2003-06-10
SK17172000A3 (sk) 2001-04-09
PL197181B1 (pl) 2008-03-31
NO20005766D0 (no) 2000-11-14
NO20005766L (no) 2001-01-12
CA2328699A1 (en) 1999-11-25
WO1999059960A1 (en) 1999-11-25
HUP0102367A3 (en) 2002-11-28
AU748397B2 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
HUP0102367A2 (hu) Citokinek által közvetített betegségek kezelésére alkalmas benzamidszármazékok
HUP0104060A2 (hu) Benzamid-származékok és felhasználásuk citokin-inhibitorként, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
HUP0103366A2 (hu) Citokin inhibítorként használható amidszármazékok
DK0685479T3 (da) Heterocyclylcarbonylsubstituerede benzofuranyl- og -thiophenylalkancarboxylsyrederivater
DE69725113D1 (de) Azetidin- und Pyrrolidinderivate
DK1119362T3 (da) Anvendelse af tetracyclinderivater til forögelse af interleukin-10-produktion
LTC1755590I2 (lt) Glikopirolato ir beta2 adrenoceptoriaus agonisto derinys
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
DE60336014D1 (de) Pyrrolobenzodiazepine zur behandlung proliferativer erkrankungen
HUP0000426A2 (hu) Új benzonaftiridinek, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
ATE451922T1 (de) Verwendung von thiazolidinon-derivaten zur behandlung von festen tumoren
HUP0401499A2 (hu) Indolszármazékok, mint COX II inhibítorok
CA2321188A1 (en) Derivatives of azetidine and pyrrolidine
NZ600342A (en) Carboxamide compounds and their use as calpain inhibitors
NO20022976L (no) 2-(1H-indol-3yl)-2-okso-acetamider med antitumoraktivitet
HUP0301706A2 (hu) Comt gátló hatással rendelkezż kumarinszármazékok, ilyen vegyületeket tartalmazó gyógyászati készítmények és alkalmazásuk
TW330198B (en) Iminooxymethyleneanilides, preparation thereof and intermediates therefor and compositions containing them
ES8407066A1 (es) Derivados de 6 -metilprednisolona.
DE69232143D1 (de) Verwendung von Amlexanox zur Herstellung eines Arzneimittels zur Behandlung von aphtösen Ulcera
MY129575A (en) Methods, kits and compositions for using pyrrole derivatives againts anxiety
MXPA04001121A (es) Derivados de fenilo.
ATE100439T1 (de) 2-(2-hydroxy-3-phenoxypropylamino)-ethoxybenzol derivate.
HUP0002826A2 (hu) 6-Azauracil-származékok, eljárás előállításukra, alkalmazásuk gyulladások elleni gyógyszer előállítására és az ilyen kompozíciók
DE60004377D1 (de) Oral wirksame 7-alpha-alkyl androgene
AP2000002001A0 (en) Hydroxamic acid derivatives as inhibitors of the production of human CD23 and of the tnf relaease.